Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 117, doi. 10.1002/cpdd.974
- Publication type:
- Article
Works matching IS 2160763X AND DT 2023 AND VI 12 AND IP 2
Results: 13
1
2
A Study to Evaluate Relative Bioavailability, Food Effect, and Pharmacodynamics of Tropifexor, a Farnesoid X Receptor Agonist, in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 122, doi. 10.1002/cpdd.1208
- By:
- Publication type:
- Article
3
Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 219, doi. 10.1002/cpdd.1207
- By:
- Publication type:
- Article
4
Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 132, doi. 10.1002/cpdd.1204
- By:
- Publication type:
- Article
5
First‐in‐Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15‐Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 141, doi. 10.1002/cpdd.1203
- By:
- Publication type:
- Article
6
Bioequivalence and Pharmacokinetic Profiles of 2 Trimetazidine Modified‐release Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 212, doi. 10.1002/cpdd.1200
- By:
- Publication type:
- Article
7
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 175, doi. 10.1002/cpdd.1197
- By:
- Publication type:
- Article
8
Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: An Open‐Label, Sequential Crossover, Self‐Control, 3‐Period Study in Healthy Chinese Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 168, doi. 10.1002/cpdd.1198
- By:
- Publication type:
- Article
9
A Randomized, Single‐dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 181, doi. 10.1002/cpdd.1189
- By:
- Publication type:
- Article
10
Safety, Pharmacokinetics, and Biomarkers of an Amorphous Solid Dispersion of Genistein, a Radioprotectant, in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 190, doi. 10.1002/cpdd.1188
- By:
- Publication type:
- Article
11
Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 159, doi. 10.1002/cpdd.1186
- By:
- Publication type:
- Article
12
Effect of Severe Renal Impairment on Pharmacokinetics, Safety, and Tolerability of ACT‐1014‐6470, a Novel Oral Complement Factor 5a Receptor 1 Antagonist.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 152, doi. 10.1002/cpdd.1184
- By:
- Publication type:
- Article
13
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose).
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 202, doi. 10.1002/cpdd.1162
- By:
- Publication type:
- Article